Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
55.50    -0.50 (-0.89%)
Bid:
55.00
Ask:
56.00
Spread: 1.00 (1.818%)
Market Cap: £8.45m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Share Repurchase Programme

22 Feb 2022 07:01

RNS Number : 3474C
Transense Technologies PLC
22 February 2022
 

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018)

 

 

Transense Technologies plc

("Transense" or "the Company")

 

Share Repurchase Programme

 

Transense Technologies plc (AIM: TRT), the developer of specialist sensor systems, is pleased to announce that it will commence a programme to conduct market purchases of ordinary shares of 10 pence each in the Company ("Ordinary Shares") up to a maximum aggregate purchase price of £300,000 (the "Programme").

 

The Company has entered into an arrangement with Shard Capital Stockbrokers ("Shard") in relation to the Programme where Shard will make the trading decisions concerning the timing of the market purchases of Ordinary Shares independently of and uninfluenced by the Company, with such trading decisions being in accordance with the terms of the Programme. Purchases may continue during any periods during the term of the Programme when the Company itself would be prohibited from dealing by the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018) ("UK MAR"). The Company reserves the right to terminate the programme if at any time it deems this to be appropriate and would make an announcement in advance of so doing.

 

The Company confirms that it currently has no unpublished inside information.

 

The Programme will commence today, 22 February 2022, and will continue until 31 October 2022 unless terminated earlier.

 

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 23 November 2021 to purchase up to 1,643,774 Ordinary Shares. This authority will expire at the earlier of the end of the next Annual General Meeting of the Company or 23 February 2024.

 

Any market purchases will be conducted in compliance with the following restrictions regarding price conditions:  

· the minimum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be its nominal value of 10 pence

· the maximum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be the higher of: (i) an amount equal to 5 per cent, above the average of the middle market quotations of an Ordinary Share as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the date of such purchase, and (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out.

 

Due to the limited liquidity in the Ordinary Shares, any market purchase of Ordinary Shares pursuant to the Programme on any trading day could represent a significant proportion of the daily trading volume in the Ordinary Shares on AIM and could exceed 25 per cent. of the average daily trading volume. This means that the Company will not benefit from the exemption contained in Article 5(1) of UK MAR.

 

The objective of the Programme is to offset the dilutive impact of share awards to directors and employees.

 

Ordinary Shares acquired as a result of the Programme will be held by the Company in treasury and in accordance with the Companies Act 2006, will not have any voting rights. It is anticipated that any Ordinary Shares held in treasury but surplus to unexercised option requirements from time to time will be cancelled.

For further information please visit www.transense.com or contact:

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter / George Payne (Corporate Finance)

Tony Quirke (Sales and Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper/Nick Rome/Nicholas Johnson

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

 

Notes to Editors:

 

Transense develops and supplies wireless sensor technology and systems. The Company has three business areas:

· SAW, patent protected Surface Acoustic Wave sensor technology that provides real time measurement of torque, temperature, pressure and strain, that is used to improve efficiency, performance and safety of propulsion systems and machinery;

· Translogik, smart, connected commercial vehicle tyre inspection equipment, used by vehicle fleets to more easily gather and maintain accurate tyre safety and condition data; and

· iTrack, a tyre pressure monitoring system for off-highway machinery, licensed exclusively to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal.

Target market sectors include automotive, aerospace and industrial machinery. The Group's strategy is to leverage excellence in innovation, know-how in wireless sensor technologies and form industry partnerships in these global growth sectors to maximise shareholder value through sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik.

Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999.

For further information please contact transense@walbrookpr.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSKFLFLLLLEBBK
Date   Source Headline
27th May 20227:00 amRNSTransaction in own shares & TVR
26th May 20223:57 pmRNSHolding(s) in Company
24th May 20227:15 amRNSTransaction in own shares & TVR
19th May 20227:00 amRNSTransaction in Own Shares & TVR
17th May 20227:00 amRNSTRT wins place on TDAP & £135k Grant
16th May 20227:00 amRNSTransaction in Own Shares & TVR
11th May 20227:00 amRNSSAW Update
9th May 20227:00 amRNSTransaction in own shares & TVR
3rd May 20227:00 amRNSTransaction in own shares & TVR
26th Apr 20228:54 amRNSTransaction in Own Shares
19th Apr 20227:00 amRNSTransaction in Own Shares
2nd Mar 20225:15 pmRNSHolding(s) in Company
28th Feb 20227:00 amRNSDirector/PDMR - acquisition of shares
22nd Feb 20227:02 amRNSGrant of share options to employees
22nd Feb 20227:01 amRNSShare Repurchase Programme
22nd Feb 20227:00 amRNSInterim Results & Investor Presentation
31st Jan 20227:00 amRNSNotice of Results & Investor Presentation
23rd Dec 20212:51 pmRNSHolding(s) in Company
22nd Dec 20214:11 pmRNSDirector/PDMR Shareholding
7th Dec 20214:25 pmRNSDirector/PDMR Shareholding
30th Nov 20217:00 amRNSDirector/PDMR Shareholding - Acquisition of Shares
24th Nov 20217:00 amRNSDirector/PDMR shareholding – acquisition of shares
23rd Nov 202112:47 pmRNSResult of AGM
23rd Nov 20217:00 amRNSAGM Trading Update and Director Appointments
11th Nov 202111:40 amRNSHolding(s) in Company
2nd Nov 20217:01 amRNSAppointment of Additional SAWCAP Member
2nd Nov 20217:00 amRNSAGM Attendance & Investor Presentation
27th Oct 20217:00 amRNSAnnual Report, Notice of AGM & Investor Pres
4th Oct 20217:00 amRNSGrant of Options/PDMR Dealing
28th Sep 20217:00 amRNSFinal Results & Investor Presentation
14th Sep 20217:00 amRNS5 year JCA with McLaren Applied Ltd for SAW Tech
3rd Sep 20214:38 pmRNSHolding(s) in Company
31st Aug 20215:00 pmRNSTotal Voting Rights
26th Aug 20217:00 amRNSNotice of Annual Results & Investor Presentation
18th Aug 20213:30 pmRNSExercise of warrants
23rd Jul 20217:00 amRNSDirector/PDMR Shareholding
21st Jul 20217:00 amRNSNew member of Commercial Advisory Panel
5th Jul 20217:00 amRNSYear End Trading Update
2nd Jul 20211:12 pmRNSHolding(s) in Company
23rd Jun 20217:00 amRNSDirector/PDMR Shareholding
9th Apr 202110:05 amRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
19th Feb 20214:12 pmRNSHolding(s) in Company
18th Feb 20211:21 pmRNSDirector/PDMR shareholding
17th Feb 202110:34 amRNSDirector/PDMR shareholding
17th Feb 20217:00 amRNSInterim Results & Investor Presentation
12th Feb 202112:48 pmRNSFurther re. Completion of Capital Reduction
1st Feb 20217:00 amRNSNotice of Results & Investor Presentation
28th Jan 20217:00 amRNSCompletion of Capital Reduction
21st Dec 20207:00 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.